Meet ApplyKite Twin, the application assistant that learns with you

Meet your Twin, it learns with you

Your Twin learns with you

Launch week codes:30% off annual Pro20% off monthly Pro

Ends in00h00m00s

Joseph Tuscano

University of California Davis Comprehensive Cancer Center

United States

Research Interests

Explore related searches

Articles (20)

Collaborators (6)

Matthew Mei

Associate Professor

City of Hope

UNITED STATES

Paul Frankel

Research Professor

Beckman Research Institute, City of Hope

UNITED STATES

Dimitrios Tzachanis

Professor of Medicine

University of California, San Diego

UNITED STATES

Joseph Michael Unger

Fred Hutchinson Cancer Research Center

UNITED STATES

Emanual Maverakis

University of California, Davis

UNITED STATES

Brian A. Jonas

Chief, Division of MHCTT

University of California Davis Comprehensive Cancer Center

UNITED STATES

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Joseph Tuscano

Research Interests

Explore related searches

Articles (20)

Collaborators (6)

Matthew Mei

Paul Frankel

Dimitrios Tzachanis

Joseph Michael Unger

Emanual Maverakis

Brian A. Jonas

Make your next move.

Joseph Tuscano

Research Interests

Explore related searches

Articles (20)

Inhibition of ROR1 signaling with zilovertamab plus ibrutinib in chronic lymphocytic leukemia: safety, mechanistic insights, and an exploratory signal in del(17p) disease

Clarithromycin, ixazomib, pomalidomide, dexamethasone for relapsed/refractory myeloma: survival and correlative analysis

A phase 1 trial of ibrutinib and azacitidine for higher risk myelodysplastic syndromes (University of California Hematologic Malignancies Consortium Study 1503)

Nivolumab-AVD Versus Brentuximab Vedotin–AVD in Older Patients With Advanced-Stage Classic Hodgkin Lymphoma Enrolled on S1826

A SYSTEMATIC REVIEW AND META‐ANALYSIS OF LENALIDOMIDE AND ANTI‐CD20 MONOCLONAL ANTIBODY THERAPY IN FOLLICULAR LYMPHOMA

A UC HEMATOLOGIC MALIGNANCY CONSORTIUM PHASE II TRIAL OF OBINUTUZUMAB, IBRUTINIB AND VENETOCLAX IN PATIENTS WITH PREVIOUSLY UNTREATED FOLLICULAR LYMPHOMA

INTENSIFIED CYCLOPHOSPHAMIDE, BORTEZOMIB, DEXAMETHASONE FOR THE TREATMENT OF NEWLY DIAGNOSED MULTIPLE MYELOMA WITH ACUTE KIDNEY INJURY

A Phase I Study of CD19 CAR T-Cells with Escalating Doses of Lymphodepletion with or without Rituximab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma

B-Cell Lymphomas 3.2025 Featured Updates to the NCCN Guidelines

Light chain crystalline podocytopathy caused by electron-lucent crystals–a diagnostic challenge: a case report

Lymphoma Therapy Response Assessment with Low-Dose [18F]FDG Total-Body PET/CT

The Impact of Social Determinants of Health on Peripheral T Cell Lymphoma Outcomes: Treatment Center-Type Emerges as a Powerful Prognostic Indicator

Nivolumab+AVD in Advanced-Stage Classic Hodgkin's Lymphoma.

A phase I trial of CC-486, lenalidomide, obinutuzumab in relapsed/refractory indolent non-Hodgkin lymphoma

A Phase II Study of Brentuximab Vedotin and Bendamustine for Relapsed/Refractory Follicular Lymphoma

Updated Results of a Phase I Study of Uproleselan Combined with Azacitidine and Venetoclax for the Treatment of Older or Unfit Patients with Treatment Naïve Acute Myeloid Leukemia

Cellular therapy in older adults with relapsed/refractory diffuse large B-cell lymphoma

Long-Axial Field-of-View PET Imaging in Patients with Lymphoma

Atezolizumab combined with immunogenic salvage chemoimmunotherapy in patients with transformed diffuse large B-cell lymphoma

Fermented Wheat Germ Protein with Histone Deacetylase Inhibitor AR42 Demonstrates Enhanced Cytotoxicity against Lymphoma Cells In Vitro and In Vivo

Collaborators (6)

Matthew Mei

Paul Frankel

Dimitrios Tzachanis

Joseph Michael Unger

Emanual Maverakis

Brian A. Jonas

Make your next move.